Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results
This article was originally published in Pharmaceutical Approvals Monthly
Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.
You may also be interested in...
FDA’s Antiviral Drugs Advisory Committee takes up the four-drug HIV-1 regimen, which includes two new agents, on May 11. The firm hopes to be able to sell the combination in part on its favorable side effects profile if the product is approved.
Phase II results presented at International AIDS Society meeting fuel speculation about co-formulations with other HIV drugs, including ViiV's Epzicom and Gilead's Truvada.
Merck's success with its HIV drug Isentress - the first and only integrase inhibitor on the market - and a recent shift in treatment guidelines that favor still greater use, are good signs for the emerging next-generation contenders in the class